National guidelines for a novel therapy: Update on clinical trials and experience using consensus panel recommendations for incorporating omalizumab into asthma management

P and T

Volumn 31, Issue 5, 2006, Pages 276-282

  Baumel, Mark J ^a   Du Buske, Lawrence ^b,c   Szefler, Stanley J ^d,e   Rosenwasser, Lanny ^f   Nash, David B ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c Immunology Research Institute of New England   (United States)

^d Department of Pediatric Clinical Pharmacology ^*

^e NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^f UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; CROMOGLYCATE DISODIUM; FLUTICASONE PROPIONATE PLUS SALMETEROL; IMMUNOGLOBULIN E; LEUKOTRIENE; NEDOCROMIL SODIUM; OMALIZUMAB; THEOPHYLLINE;

ALLERGIC REACTION; ASTHMA; CLINICAL FEATURE; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED DRUG RELEASE; CONTROLLED RELEASE FORMULATION; DISEASE CONTROL; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG BINDING; DRUG BLOOD LEVEL; DRUG DOSAGE FORM; DRUG EFFICACY; DRUG INHIBITION; EOSINOPHIL; FOOD AND DRUG ADMINISTRATION; HEALTH CARE UTILIZATION; HEALTH PRACTITIONER; HUMAN; MAST CELL; MEDICAL PRACTICE; MEDICAL SPECIALIST; PATHOGENESIS; PRACTICE GUIDELINE; PROPHYLAXIS; PULMONOLOGY; QUALITY OF LIFE; RADIOALLERGOSORBENT TEST; REVIEW; SYRUP; TABLET; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT;

EID: 33744904963     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. Weiss KB, Sullivan SD, Lyttle CS. Trends in the cost of illness for asthma in the United States, 1985-1994. J Allergy Clin Immunol 2000;106:493-499.
2. Smith DG, Malone DC, Lawson KA, et al. A national estimate of the economic costs of asthma. Am J Respir Crit Care Med 1997; 156:787-793.
3. Dolan CM, Fraher KE, Bleecker ER, et al. TENOR Study Group. Design and baseline characteristics of the Epidemiology and Natural History of Asthma Outcomes and Treatment Regimens (TENOR) study: A large cohort of patients with severe or difficult-to-treat asthma. Ann Allergy Asthma Immunol 2004;92(1):32-39.
4. Burrows B, Marinez FD, Halonen M, et al. Association of asthma with serum IgE levels and skin-test reactivity to allergens. N Engl J Med 1989;320:271-277.
5. Bachert C, vanCauwenberg P, Khaltaev N. World Health Organization: Allergic Rhinitis and its Impact on Asthma (ARIA). Executive Summary of Workshop Report, 7-10 December 1999. Available at: www.who.int/entity/mediacentre/ factsheet/fs206.
6. Fahy JV, Fleming E, Wong HH, et al. The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med 1997;155:1828-1834.
7. MacGlashan DW Jr, Bochner BS, Adelman DC, et al. Down-regulation of Fc(ε)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol 1997;158(3):1438-1445.
8. Buhl R, Hanf G, Soler M, et al. The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma. Eur Respir J 2002;20:1088-1094.
9. Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001;108:184-190.
10. Corren J, Casale T, Deniz Y, Ashby M. Omalizumab, a recombinant humanized anti-IgE antibody, reduces asthma-related emergency room visits and hospitalizations in patients with allergic asthma. J Allergy Clin Immunol 2003;111:87-90.
11. Soler M, Matz J, Townley R, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Resp J 2001;18:254-261.
12. Chipps BE, Marshik PL. Targeted IgE therapy for patients with moderate to severe asthma. Biotechnol Healthcare 2004;1:56-61.
13. National Asthma Education and Prevention Program. Clinical Practice Guidelines: Expert Panel Report 2. Guidelines for the Diagnosis and Management of Asthma. Bethesda: National Institutes of Health; July 1997. Available at: www.nhlbi.nih.gov. guidelines/asthma/asthgdln.pdf.
14. Global Initiative for Asthma (GINA). Available at: www. ginasthma.com.
15. British Guideline on the Management of Asthma. Available at: www.brit-thoracic.org.uk/asthma-guideline-download.html.
16. Canadian Asthma Consensus Guidelines. Available at: www. asthmaguidelines.com.
17. Rosenwasser IJ, Nash DB. Incorporating omalizumab into asthma treatment guidelines: Consensus panel recommendations. P&T 2003;28(6):400-410.
18. Current dynamics in commercial payer restrictions on Xolair: Data from the Prior Authorization Tracking Tool (PATT). San Francisco, CA: Zitter Group Strategy and Analytics; February 26, 2005.
19. Adams RJ, Fuhlbrigge A, Guilbert T, et al. Inadequate use of asthma medication in the United States: Results of the asthma in America national population survey. J Allergy Clin Immunol 2002; 110:58-64.
20. Lai CKW, de Guia TS, Kim Y-Y, et al. Asthma control in the Asia-Pacific region: The Asthma Insights and Reality in Asia-Pacific Study. J Allergy Clin Immunol 2003;111:263-268.
21. Rabe Kf, Vermeire PA, Soriano J, Maier WC. Clinical management of asthma in 1999: The Asthma Insights and Reality in Europe (AIRE) study. Eur Respir J 2000;16:802-807.
22. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. NIH Publication 02-3659. Available at: www.ginasthma.com.
23. Bateman ED, Boushey HA, Bousquet J, et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma controL Study [GOAL]. Am J Respir Crit Care Med 2004;170:836-844.
24. Szefler SJ, Martin RJ, King TS, et al. Significant variability in response to inhaled coricosteroids for persistent asthma. J Allergy Clin Immunol 2002;109:410-418.
25. Humbert M, Beasley R, Ayres J, Slavin R, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005;60(3):309-316.
26. Bousquet J, Wenzel S, Holgate S, et al. Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma. Chest 2004;128:1378-1386.